3,716 Shares of AbbVie Inc. $ABBV Purchased by Vista Capital Partners Inc.

Vista Capital Partners Inc. acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the third quarter, HoldingsChannel.com reports. The fund acquired 3,716 shares of the company’s stock, valued at approximately $972,000.

A number of other institutional investors have also made changes to their positions in the stock. State Street Corp boosted its position in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Fisher Asset Management LLC grew its holdings in AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares during the last quarter. Corient Private Wealth LP bought a new position in shares of AbbVie in the second quarter valued at approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of AbbVie in the second quarter valued at approximately $2,905,952,000. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Up 0.1%

Shares of NYSE ABBV opened at $295.18 on Monday. The business’s 50 day moving average is $275.51 and its two-hundred day moving average is $240.91. The company has a market cap of $521.77 billion, a P/E ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same period in the previous year, the company earned $1.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Sell-side analysts expect that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is presently 119.10%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABBV. Canaccord Genuity Group boosted their price objective on shares of AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research note on Monday, November 2nd. Leerink Partners raised their target price on shares of AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a research note on Monday, November 2nd. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. HSBC boosted their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Guggenheim upped their price target on shares of AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $297.46.

Get Our Latest Stock Report on AbbVie

Insider Transactions at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.